Introduction
Although a variety of approaches are available for treating retinal pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD), no unified methodology has yet been approved and/or overwhelmingly favored.
The use of retinal laser photocoagulation (RLP) for this purpose began in the 1980s and 1990s. It has been demonstrated in multiple studies that RLP results in developing an RPE tear, subretinal neovascular membranes (SNMs), retinal atrophy and abrupt decrease in central vision [1, 2] . Subsequently, inadequate efficacy of photodynamic therapy for this disorder was reported [3, 4] .
Although in recent years, increasing attention has been focused on vascular endothelial growth factors (VEGF), the use of VEGF inhibitors in serous PED often results in developing an RPE tear and loss of central vision [5] [6] [7] .
More recently, publications have appeared on the use of combination therapy in exudative AMD. A number of studies have demonstrated improved outcomes for patients with this disorder treated with combination of laser therapy, anti-VEGF agents and triamcinolone acetonide (TA) [8] [9] [10] .
Triamcinolone acetonide is a long-acting synthetic steroid with anti-inflammatory and anti-edematous effects. The efficacy of intravitreal and subtenon TA for diabetic macular edema, retinal vein occlusionrelated macular edema, and rhegmatogenous retinal detachment has been already well studied [11] [12] [13] [14] . Given the avascular nature of PED, the presence of elements of inflammation in the pathogenesis of, and the improved efficacy of treating PED with a combination including TA, we have hypothesized previously that this disorder, when associated with AMD may be treated with a TA monotherapy [15] .
The purpose of the study was to investigate the effect of a long-acting steroid on the structural and functional RPE features in serous PED associated with AMD in long-term follow-up study, and to improve the efficacy of treatment of this disorder through the use of steroid therapy based on the findings of this investigation.
Materials and Methods
This was a prospective, single-centre, comparative study. Fifty-two patients (54 eyes) with serous PED associated with AMD were followed up. They were divided into subtenon and intravitreal groups comprising 30 patients (32 eyes) and 22 patients (22 eyes), respectively, and treated with 0.5 ml (40 mg) subtenon TA suspension and 0.1 ml (4 mg) intravitreal TA crystals, respectively, as needed.
A repeat injection was made at 3 months after previous injection, if no decrease in OCT-derived dimensions over this 3-month period was observed.
The control data of the Moorfields macular study group based on the controlled trial of argon laser photocoagulation for PEDs in the elderly were used as controls [16, 17] .
At baseline, complaints were collected and detailed histories were taken. Thereafter, patients underwent a general eye examination including visual acuity assessment and ophthalmoscopy. In addition, they underwent ocular imaging with color fundus photography, long-wave fundusgraphy, fluorescein angiography and macular optical coherence tomography (OCT). OCT-derived retinal structural parameters, maximum PED height and length at different meridians, were investigated. A general eye examination and ocular imaging studies were performed at baseline and at 1, 3, 6, 9, 12, 15, 18, 24, 30 and 36 months.
Primary efficacy endpoints were stabilization of visual acuity and complete re-attachment of the RPE. Major secondary efficacy endpoints included ocular adverse events such as RPE tears, formation of subretinal neovascular membranes and RPE atrophy. Patients of the study were followed up at the Laser Eye Microsurgery Department of the Filatov Institute of Eye Disease.
The statistical package StatSoft© Statistica® 10.0 (StatSoft, Tulsa, OK) was used for development of a primary database, data processing and plotting. Repeated measures ANOVA were conducted to examine posttreatment changes in variables over time. The MannWhitney rank test was used for data comparison at each of the follow-up time points between groups. The McNemar test was used to assess the treatment efficacy in each arm, and the groups were compared for efficacy using 95% confidence intervals. P < 0.05 was considered statistically significant in all the analyses.
Results and Discussion
Fifty-two patients (54 eyes; male-to-female percentage, 39.4% to 60.6%; mean age, 66.0 (SD 7.5) years; age range, 47 to 85 years) with serous PED associated with AMD received a complete course of the study.
There was no significant difference in the baseline mean visual acuity (SD) between those who received intravitreal TA and those who received subtenon TA (mean (SD), 0.4 (0.3) μm versus 0.45 (0.33); P = 0.6). At 36 months, the mean visual acuity (SD) in the intravitreal group was 0.38 (0.3) (P = 0.7) versus 0.45 (0.33) in the subtenon group (P = 0.8). At the final follow-up time point, no significant difference in visual acuity between the two groups was observed (P = 0.4). In each of the two groups, no significant decrease in visual acuity was observed over the 36-month follow-up period ( Fig. 1) .
At the next stage of the study, we assessed changes in height and length of serous PED in AMD in the presence of treatment with TA at each of the follow-up time points.
There was no significant difference in the baseline height of serous PED between those who received intravitreal TA and those who received subtenon TA (mean (SD), 486 (187) μm versus 446 (199); P = 0.4). At 36 months, the height of serous PED in the intravitreal group was 256 (139) μm versus 231 (107) μm in the subtenon group (Fig. 2) , with no significant difference in the height between the two groups (P = 0.7). A significant decrease in the height of RPE detachment was observed in both groups over the 36-month followup period (Fig. 3) .
There was no significant difference in the baseline length of serous PED between those who received intravitreal TA and those who received subtenon TA (mean (SD), 1859 (911) μm versus 2055 (587) μm; P = 0.3). At 36 months, the length of serous PED in the intravitreal group and in the subtenon group was 1112 (451) μm and 1423 (465) μm, respectively, with no significant difference in the length of serous PED between the groups (P = 0.17). We found a significant decrease in the length of PED in both groups over the 36-month follow-up period (Fig. 4) .
The mean number of injections in the intravitreal group was 3.6 (1.7) versus 5.2 (2.1) in the subtenon group, with a significant difference between the groups (P = 0.005).
A primary outcome was complete re-attachment of the RPE. At the final follow-up time point (36 months), complete re-attachment of the RPE was achieved in 20 of 54 eyes (37%) treated with TA, and this rate was 36.4% in the intravitreal group versus 37.5% in the subtenon group, with no significant difference between the two routes of administration of TA (P = 0.9). Over a 36-month follow-up period, RPE re-detachments occurred in 3 eyes (13.6%) of the intravitreal group, with no significant difference in this rate between the two groups (P = 0.15).
At 30 months, subretinal neovascular membranes formed in 2 eyes of the intravitreal group versus 3 eyes of the subtenon group. At 36 months, subretinal neovascularization was found in 2 more eyes of the intravitreal group. Over the 36-month follow-up period, SNMs formed in 4/22 (18%) of eyes of the intravitreal group versus 3/32 (9%) of eyes of the subtenon group, with no significant difference in SNM formation rate between the two groups (P = 0.34). Therefore, over a 3-year observation period, subretinal neovascularization developed in 7 eyes (13%) of the study patients.
RPE atrophy was found in 1 eye (2%) of the subtenon group at 24 months.
No case of RPE tear, infectious complication, retinal detachment or cardiovascular complication was noted over the 36-month follow-up period.
Currently, little is known of (a) the changes in visual acuity and structural characteristics of PED over time following introduction of TA into the eye, (b) factors influencing the efficacy of TA in the treatment of this disorder and the risk of developing complications, (c) prognosis for late outcomes of TA treatment in serous PED in a long-term follow-up.
In the controlled trial of argon laser photocoagulation in PEDs in the elderly [16, 17] , a reduction in VA was noted in 27 patients (27 eyes) of the untreated group at 9 months. Control eyes continued to show gradual but progressive visual loss at the following visits. At 3 years, a visual loss of 0.25 (or 2.42 Snellen lines) was observed in 19 (86%) of untreated eyes, and 14% of control eyes remained stable compared to the baseline values. In addition, in 22 patients (22 eyes) with PED treated with laser photocoagulation, visual loss was noted as early as 3 months. Although that study showed a reduction in PED in most of the treated eyes, their VA continued to decrease, and, at 36 months, a visual loss of 2.93 Snellen lines was found in 15 treated eyes (75%), and 15% of treated eyes remained stable compared to the baseline values [16, 17] .
Over the course of our study, visual acuity in both arms of the study remained stable compared to the baseline values.
In 2001, Gomez-Ulla and colleagues [2] reported that at 25 months, out of 11 eyes treated with diode laser photocoagulation for RPE detachment, 6 eyes (55%) improved or stabilized VA, and the rest showed no change in VA. De Jong [18] and Ho and colleagues [19] demonstrated that laser photocoagulation did not result in improvement in vision in patients with serous PED associated with AMD.
PDT is not used in patients with avascular serous PED associated with AMD. However, PDT for CNV associated with PED in AMD has been shown to result in decreased visual function. Thus, Pece and colleagues demonstrated that in eyes with CNV at the edge of PED treated with PDT, the mean preoperative visual acuity changed from 20/80 (0.60 ± 0.33 logMAR) to 20/126 (0.80 ± 0.64 logMAR) at month 18. The authors of that study believe that this was caused by post-PDT complications (subretinal hemorrhage, increase in RPE detachment and RPE tears) [20] . Subsequently, Ladas and colleagues [21] demonstrated a statistically significant visual loss of at least 3 lines following PDT for CNV associated with PED (of at least 1 disc diameter in size) in AMD in 77.3% of eyes at the completion of follow-up (12 to 48 months) [21] .
According to Panos et al [6] , Kook et al [7] , and Lommatzsch and co-authors [22] , the use of angiogenesis inhibitors (bevacizumab and ranibizumab) in serous PED results in stabilization of visual acuity over the entire period of treatment; however, the use of anti-VEGF agents for this purpose is associated with high risk of RPE tear which may be followed by a sudden and irreversible loss of vision.
In the study presented here, complete re-attachment of the RPE was observed in 20 eyes (37%) treated with TA over the 36-month follow-up period, and the reattachment rate in the intravitreal group was 36.4% (8 eyes out of 22) versus 37.5% (12 eyes out of 32) in the subtenon group. At the final follow-up time point, there was no significant difference in the reattachment rate between the two administration arms (P = 0.9). However, the number of injections needed was statistically significantly higher for subtenon TA treatment than for intravitreal TA treatment of serous PED associated with AMD.
Some authors [20, 23, 24] believe that the initial size of PED is an important prognostic factor. Thus, Lasic and Gabric [24] have reported on the outcomes of intravitreal bevacizumab treatment of 102 patients with RPE detachment associated with AMD, with median duration of follow-up of 18 weeks, and finding of direct correlation between the baseline PED height and treatment outcome. In addition, they found that the anti-VEGF agent was of low efficacy in patients with a high pre-injection PED [24] .
During the course of our study of PED treatment with TA, we found no cases of RPE tear. This is an evidence for the pathogenetic validity of the use of TA monotherapy for serous PED.
The formation of SNM was another type of ocular adverse events evaluated in our study. During the 36-month observation period, SNM developed in 7 eyes out of 54 (13%), including 4/22 (18%) eyes of the intravitreal group and 3/32 (18%) eyes of the subtenon group, with no significant intergroup difference (P = 0.34). It is noteworthy that the first case of SNM formation in our study was observed as late as month 30.
During the 3-year observation period in the study conducted by the Moorfields macular study group, SNM developed in 10 (45%) untreated eyes with PED, which is 35% higher than the rate in our study (95% CI = 12.4 to 55.6; P = 0.004). In addition, SNM developed in 8 (40%) eyes treated with laser photocoagulation for PED, which is 25% higher than that in the use of TA for this disorder (95% CI = 3.4 to 47.5; P = 0.04) [17] . It is noteworthy that the first SNM formation event in untreated patients of that study was noted at month 18 [17] . Therefore, in our study, in patients treated with TA, subretinal neovascular membrane developed 2 years later compared to treatment-naпve patients.
To the best of our knowledge, no case of SNM development in serous PED treated with PDT and intravitreal anti-VEGF agents has been reported [25, 26] .
Therefore, in our study, SNMs developed in 13% of treated eyes, with the first case of SNM formation observed as late as month 30, which is substantially less frequently and later than in other studies.
In the study reported by the Moorfields macular study group [17] , by month 36, RPE atrophy was found in 5 (23%) untreated eyes with PED, and in 10 (50%) eyes treated with laser photocoagulation for PED, while in our study, geographic RPE atrophy was found in 1 (2%) eye treated with TA for PED at month 36.
Siqueira and colleagues [27] and Miura and Roiter [28] have demonstrated in their in vivo and in vitro experimental studies that long-acting steroids strengthen intercellular bonds in the RPE, resulting in decreased permeability of cellular membranes. This contributes to protection of RPE cells from oxidative injury followed by cell destruction [27, 28] .
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Therefore, this confirms the pathogenetic validity of the use of TA monotherapy for serous PED.
At the final follow-up time point, no significant difference in visual acuity, and percentages of eyes with re-attachment of the RPE, RPE tears, formations of SNM, or RPE atrophy events between the two administration arms of triamcinolone acetonide was observed. Therefore, the route of administration of TA did not influence the efficacy of TA therapy.
Conclusion
Intravitreal and subtenon TA injection therapy have similar efficacy in serous retinal pigment epithelial detachment associated with age-related macular degeneration, and contribute to the maintenance of visual acuity throughout 36 months.
We found significant reductions in the height and length of pigment epithelial detachment in patients who received intravitreal TA (from 486 (187) μm to 256 (139) μm, P = 0.005; and from 1859 (911) μm to 1112 (451) μm, P = 0.04, respectively) and in those who received subtenon TA (from 446 (199) μm to 231 (107) μm, P = 0.0001; and from 2055 (587) μm to 1423 (465) μm, P = 0.02, respectively).
Complete re-attachment of the RPE was achieved in 37% of eyes treated with TA.
Irrespective of the route of administration, TA therapy allowed us to prevent RPE tears in patients with serous retinal pigment epithelial detachment associated with age-related macular degeneration throughout the 36-month follow-up period.
It was established that, in patients treated with TA, subretinal neovascular membrane develops 2 years later compared to treatment-naпve patients. 
